SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Guo ZY)
 

Search: WFRF:(Guo ZY) > (2020-2024) > Bupi Yishen Formula...

  • Mao, W (author)

Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-01-29
  • Frontiers Media SA,2021

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:145941019
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:145941019URI
  • https://doi.org/10.3389/fphar.2020.627185DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic CKD4. This trial was a multicenter, double-blind, double-dummy, randomized controlled trial that was carried out from 11-08-2011 to 07-20-2015. Patients were assigned (1:1) to receive either BYF or losartan for 48 weeks. The primary outcome was the change in the slope of the estimated glomerular filtration rate (eGFR) over 48 weeks. The secondary outcomes were the composite of end-stage kidney disease, death, doubling of serum creatinine, stroke, and cardiovascular events. A total of 567 patients were randomized to BYF (n = 283) or losartan (n = 284); of these, 549 (97%) patients were included in the final analysis. The BYF group had a slower renal function decline particularly prior to 12 weeks over the 48-week duration (between-group mean difference of eGFR slopes: −2.25 ml/min/1.73 m2/year, 95% confidence interval [CI]: −4.03,−0.47), and a lower risk of composite outcome of death from any cause, doubling of serum creatinine level, end-stage kidney disease (ESKD), stroke, or cardiovascular events (adjusted hazard ratio = 0.61, 95%CI: 0.44,0.85). No significant between-group differences were observed in the incidence of adverse events. We conclude that BYF might have renoprotective effects among non-diabetic patients with CKD4 in the first 12 weeks and over 48 weeks, but longer follow-up is required to evaluate the long-term effects.Clinical Trial Registration:http://www.chictr.org.cn, identifier ChiCTR-TRC-10001518.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Yang, NZ (author)
  • Zhang, L (author)
  • Li, C (author)
  • Wu, YF (author)
  • Ouyang, WW (author)
  • Xu, P (author)
  • Zou, C (author)
  • Pei, CP (author)
  • Shi, W (author)
  • Zhan, JH (author)
  • Yang, HT (author)
  • Chen, HY (author)
  • Wang, XQ (author)
  • Tian, Y (author)
  • Yuan, F (author)
  • Sun, W (author)
  • Xiong, GL (author)
  • Chen, M (author)
  • Guan, JG (author)
  • Tang, SF (author)
  • Zhang, CY (author)
  • Liu, YN (author)
  • Deng, YY (author)
  • Lin, QZ (author)
  • Lu, FH (author)
  • Hong, WH (author)
  • Yang, AC (author)
  • Fang, JG (author)
  • Rao, JZ (author)
  • Wang, LX (author)
  • Bao, K (author)
  • Lin, F (author)
  • Xu, Y (author)
  • Lu, ZY (author)
  • Su, GBKarolinska Institutet (author)
  • Zhang, L (author)
  • Johnson, DW (author)
  • Zhao, DX (author)
  • Hou, HJ (author)
  • Fu, LZ (author)
  • Guo, XF (author)
  • Yang, LH (author)
  • Qin, XD (author)
  • Wen, ZH (author)
  • Liu, XS (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Frontiers in pharmacology: Frontiers Media SA11, s. 627185-1663-9812

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view